A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
N/A
Terminated
NCT05966740
| Condition | Venous Thromboembolism |
|---|
| Phase | N/A |
|---|
| Sponsor | Boehringer Ingelheim |
|---|
| Status | Terminated |
|---|
| Enrollment | 5 participants |
|---|
| Start date | Apr 19, 2024 |
|---|
| Completion date | Apr 28, 2025 |
|---|
| Results posted | Jun 2, 2026 |
|---|
Summary
The main research question of this study is to obtain further safety and effectiveness data on Pradaxa Pellets in children aged 3 months to less than 12 years in routine clinical practice setting.
Cumulative Incidence of Clinically Relevant Bleeding Events
From first Pradaxa Pellets exposure until its discontinuation plus 3 days of residual effect period, switch to other anticoagulation therapy, or planned observation time, whichever occurred first. Up to 373 days. · Participants
| Pradaxa-treated Patients | 1 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.